Storia in 2 fonti

China's CSPC and AstraZeneca sign $1.77b drug development deal

Chinese drugmaker CSPC Pharmaceutical Group said on Thursday that it had entered a strategic collaboration with AstraZeneca to develop small interfering RNA (siRNA) therapies for kidney diseases in a deal worth up to $1.77 billion, extending a series of partnerships between the two companies.

Raccontata da

global.chinadaily.com.cn

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

global.chinadaily.com.cnStai leggendo1 mese fa

China's CSPC and AstraZeneca sign $1.77b drug development deal

originale

endpoints.news1 mese fa

After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pact

AstraZeneca strikes another deal with CSPC, worth up to $1.7B, to develop siRNA candidates for renal diseases — months after their $18.5B obesity alliance and two deals in previous years.

Leggi questa versione →

Timeline cronologica

giovedì 2 luglio 2026·global.chinadaily.com.cn
China's CSPC and AstraZeneca sign $1.77b drug development deal
Chinese drugmaker CSPC Pharmaceutical Group said on Thursday that it had entered a strategic collaboration with AstraZeneca to develop small interfering RNA (siRNA) therapies for…
giovedì 2 luglio 2026·endpoints.news
After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pact
AstraZeneca strikes another deal with CSPC, worth up to $1.7B, to develop siRNA candidates for renal diseases — months after their $18.5B obesity alliance and two deals in…